of Diseases Treated by
Treatment of Untreatable Early Menopause by BCRO Fetal Cell Transplantation
Early menopause, where standard hormone replacement therapy has failed, is another group of diseases where BCRO fetal precursor cell transplantation has been used during the last 20 years with remarkable effectiveness. Naturally the number of patients with early menopause ('secondary amenorhea') treated by fetal precursor cell transplantation cannot be compared with those treated the 'usual menopause', among ~ 5 million of patients undergoing fetal precursor cell therapy during the last 70+ years.
Gynecologists have observed that for some reason ~ 50% of patients with early menopause do not respond well to the usual hormone replacement therapy with estrogen and progesterone, for reasons unknown.
In reality the reasons are known well. Nature must assure the continuity of life by a perfect control of procreation. Function of all organs of procreation must be perfectly regulated. The regulation in female body is not only a matter of taking estrogen and progesterone. It is run by an automonous nervous system directed by hypothalamus, a very important part of the central nervous system, and managed by the endocrine system, with the pituitary being the 'master gland', directing the rest of hormones producing glands. Lack of some hormones can be substituted by hormonal therapy, but only fetal precursor cell transplantation can treat hypothalamus, and coordinate all glands of the endocrine system, that must work together in perfect synchrony like the best symphony orchestra.
The frequency of premature menopause has been increasing with such a speed in the 'civilized' world, that U.S. gynecologists began to talk about a real 'epidemic'.
It is apparently due to the stress and pressures of high level jobs, requiring long hours, intense competition, hectic lifestyle, inadequate nutrition up to starvation, etc., that so many young women in their early thirties stop menstruating, and soon develop classical symptoms of menopause, and of its complications.
The usual physiological menopause is a normal phenomenon while premature menopause is an illness.
In not so rare instances it is due to the prolonged use of birth control pills.
Our own published studies document that patients with early menopause respond to fetal precursor cell transplantation unusually well.
The serum levels of hormones:
Immediately after the next fetal cell transplantation the level of all hormones goes back to nearly normal levels and will stay there for 6 - 7 months.
With each subsequent cell transplantation the duration of clinical effect lasts longer.
A judicious combination of fetal precursor cell transplantation with a hormone replacement therapy can bring these patient back to health.
In the 70+ years' history of fetal cell transplantation it has been used in those patients where all known therapies had failed in helping the patient.
Among those were patients with untreatable ('intractable') endometriosis.
Only those patients suffering of endometriosis understand how miserable this illness is, how the pain, and other symptoms, can drive one to suicide particularly when no treatment gives any relief.
Some such patients 'at the end of the rope' were treated by our BCRO fetal precursor cell transplants with very good results.
BCRO cell transplantation is not the treatment of choice for endometriosis, however it is an option to be used, when everything else fails.
Many western patients have undergone hysterectomy for uterine myomas, because 'the patient was of the age when it makes no difference', etc.,
just to find out that their husbands left them because of the lack of uterus, or because they gained too much weight after the operation, etc.
Patients with myomas of the uterus, in whom surgery was contraindicated, or who refused it, have been treated by fetal precursor cell transplantation. The size of uterine myomas was decreased by such therapy, and thus hysterectomy could have been avoided or postponed.
|FRAUD IN STEM CELL TRANSPLANTATION||WARRANTY/REPLACEMENT||DISCLAIMER||PRIVACY STATEMENT|
|Copyright Stem Cell Transplantation Ltd.|
|Updated: December 2018|